High dose rivastigmine in the symptom management of Lewy body dementia.

Abstract

A man presented in late 2004 at the age of 65 with a decline in memory. He was diagnosed with Lewy body dementia and started on 3 mg rivastigmine a day, which made a marked clinical improvement. He lived with the illness for 10 years, over which time the dose of acetylcholinesterase inhibitors (ChEI) he took rose to two 9.5 mg rivastigmine patches and 7.5 mg donepezil, significantly above British National Formulary (BNF) limits. He demonstrated clear clinical response to ChEI and showed improvements in alertness and functioning. He did not exhibit life-threatening cardiac side effects and his death in 2014 was not related to the ChEI.

• Authors: Joseph Marwan Nour, Leonidas Chouliaras, Lilian Hickey
• Journal: BMJ case reports (BMJ Case Rep) Vol. 2016 (Nov 29 2016) ISSN: 1757-790X [Electronic] England
• PMID: 27899389 (Publication Type: Case Reports, Journal Article)
• Copyright: 2016 BMJ Publishing Group Ltd.

Chemical References

• Cholinesterase Inhibitors
• Phenylcarbamates
• Rivastigmine

Topics

• Aged
• Cholinesterase Inhibitors (administration & dosage)
• Disease Progression
• Dose-Response Relationship, Drug
• Humans
• Lewy Body Disease (drug therapy, physiopathology)
• Male
• Phenylcarbamates
• Quality of Life
• Rivastigmine (administration & dosage)
• Treatment Outcome